Published in Mov Disord on September 01, 2006
The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics"). Sleep Med (2009) 1.96
Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol (2010) 1.70
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol (2009) 0.96
Treatment of restless legs syndrome. Neurotherapeutics (2014) 0.84
Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist. Sleep (2008) 0.82
The influence of parathyroidectomy on restless legs syndrome in patients with renal hyperparathyroidism. World J Surg (2013) 0.78
Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatr Dis Treat (2009) 0.77
Efficacy of Pramipexole for the Treatment of Primary Restless Leg Syndrome: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Clin Ther (2015) 0.76
[Iron deficiency, Fatigue and Restless-Legs-Syndrome]. Wien Med Wochenschr (2016) 0.75
[Sleep and sleep disorders in the elderly: Part 3: Restless legs syndrome]. Z Gerontol Geriatr (2015) 0.75
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med (2003) 4.95
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ (2003) 3.78
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord (2007) 2.64
A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc (2003) 2.47
Sex and the risk of restless legs syndrome in the general population. Arch Intern Med (2004) 2.43
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int (2010) 2.27
Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology (2011) 2.17
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2003) 2.03
Hyperalgesia and functional sensory loss in restless legs syndrome. Pain (2013) 2.00
Body weight in patients with Parkinson's disease. Mov Disord (2006) 1.89
Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev (2011) 1.88
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord (2009) 1.62
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol (2005) 1.58
Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol (2013) 1.55
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain (2004) 1.54
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Serum concentrations of s100b and NSE in migraine. Headache (2009) 1.48
Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med (2008) 1.48
Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev (2002) 1.46
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry (2003) 1.41
Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav (2010) 1.41
Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord (2011) 1.41
Predictors of freezing in Parkinson's disease: a survey of 6,620 patients. Mov Disord (2007) 1.39
Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol (2006) 1.38
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35
Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. Gen Hosp Psychiatry (2004) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS One (2008) 1.29
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem (2005) 1.27
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet (2011) 1.27
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion (2004) 1.26
Cytokines and epilepsy. Seizure (2011) 1.26
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci (2011) 1.24
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med (2007) 1.23
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. J Neurol (2002) 1.23
Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord (2007) 1.21
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol (2002) 1.20
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
Empirical evaluation of the accuracy of diagnostic criteria for Restless Legs Syndrome. Sleep Med (2008) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp (2011) 1.17
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord (2010) 1.16
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem (2003) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord (2011) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med (2008) 1.14
Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients' choice arm. Psychother Psychosom (2010) 1.14
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol (2014) 1.12
Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord (2010) 1.12
Pathophysiological concepts of restless legs syndrome. Mov Disord (2007) 1.12
Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med (2011) 1.12